Compare ASST & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASST | WGS |
|---|---|---|
| Founded | 2020 | 2017 |
| Country | United States | United States |
| Employees | N/A | 1300 |
| Industry | Computer Software: Prepackaged Software | Retail: Computer Software & Peripheral Equipment |
| Sector | Technology | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2022 | N/A |
| Metric | ASST | WGS |
|---|---|---|
| Price | $12.39 | $65.62 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $23.50 | ★ $120.71 |
| AVG Volume (30 Days) | ★ 4.9M | 1.0M |
| Earning Date | 05-14-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 82.56 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $633,489.00 | N/A |
| Revenue This Year | $294.91 | $29.98 |
| Revenue Next Year | $12.16 | $25.92 |
| P/E Ratio | ★ N/A | $1,251.58 |
| Revenue Growth | ★ 128.67 | N/A |
| 52 Week Low | $0.49 | $32.21 |
| 52 Week High | $19.75 | $170.87 |
| Indicator | ASST | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 41.73 | 55.31 |
| Support Level | $10.53 | $55.76 |
| Resistance Level | $17.73 | $73.46 |
| Average True Range (ATR) | 1.12 | 4.39 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 32.13 | 56.54 |
Strive Inc is a structured finance company and institutional asset manager focused on disciplined capital allocation and long term value creation. The company has adopted bitcoin as its hurdle rate for capital deployment because of its fiduciary duty to maximize long-term value for stockholders, and compounding purchasing power over time. It operates in two reportable operating segments: the Asset Management segment, which provides investment advisory services and the Corporate & Other segment, which includes the company's bitcoin treasury operations. The majority of the revenue is derived from the Asset Management segment.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.